New drug combo shows promise against Hard-to-Treat lymphomas
NCT ID NCT03598608
First seen Jan 22, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and can shrink tumors. Participants received the drugs alone or together, and researchers monitored side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351)
Bologna, Emilia-Romagna, 40138, Italy
-
BC Cancer ( Site 0107)
Vancouver, British Columbia, V5Z 1L3, Canada
-
Banner MD Anderson Cancer Center ( Site 0020)
Gilbert, Arizona, 85234, United States
-
CancerCare Manitoba ( Site 0101)
Winnipeg, Manitoba, R3E 0V9, Canada
-
Chaim Sheba Medical Center. ( Site 0380)
Ramat Gan, 5262001, Israel
-
City of Hope ( Site 0001)
Duarte, California, 91010, United States
-
Concord Repatriation & General Hospital ( Site 0203)
Concord, New South Wales, 2139, Australia
-
Dana Farber Cancer Institute ( Site 0002)
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center ( Site 0019)
Philadelphia, Pennsylvania, 19111, United States
-
Hadassah Ein Karem Jerusalem ( Site 0383)
Jerusalem, 9112001, Israel
-
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352)
Rozzano, Milano, 20089, Italy
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354)
Meldola, Forli-Cesena, 47014, Italy
-
Jewish General Hospital ( Site 0105)
Montreal, Quebec, H3T 1E2, Canada
-
Monash Health ( Site 0201)
Clayton, Victoria, 3168, Australia
-
Pacific Cancer Care ( Site 0006)
Monterey, California, 93940, United States
-
Princess Alexandra Hospital ( Site 0204)
Woollongabba, Queensland, 4102, Australia
-
Princess Margaret Cancer Centre ( Site 0100)
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Medical Center ( Site 0382)
Haifa, 3109601, Israel
-
Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)
Los Angeles, California, 90095, United States
-
Sourasky Medical Center ( Site 0381)
Tel Aviv, 6423906, Israel
-
St Vincent s Hospital (Melbourne) Limited ( Site 0202)
Fitzroy, Victoria, 3065, Australia
-
Texas Oncology-Austin Midtown ( Site 8002)
Austin, Texas, 78705, United States
-
U. klinikum Koeln AOER ( Site 0326)
Cologne, North Rhine-Westphalia, 50937, Germany
-
Universitaetsklinikum Leipzig AOeR ( Site 0327)
Leipzig, Saxony, 4103, Germany
-
University of California San Francisco ( Site 0023)
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.